EVALUATION OF ENDOTOXIN MODELS FOR THE STUDY OF SEPSIS

作者: Daniel G Remick , Peter A Ward

DOI: 10.1097/01.SHK.0000191384.34066.85

关键词: MediatorClinical trialCytokine responseImmunologyBlood volumeCytokineIn patientMedicineSepsisPathophysiology

摘要: Many strategies have been proposed for the treatment of sepsis, and most modalities failed in clinical trials. previous protocols called blocking activity a single, clearly defined mediator. The underlying hypothesis was that sepsis induced specific mediator then caused organ injury death. This simple, linear reasoning frequently based on cytokines were using endotoxin models sepsis. widely used to study pathophysiology felt adequately reproduce full spectrum inflammatory changes observed patients with Based mortality hematologic changes, these assumptions appeared justified. As examined more closely, directly compared focus infection accurately portray it became apparent did not mimic patient In models, explosive release into circulating blood volume reproducibly found regardless species studied (human, primate, pig, rat, or mouse). lead series anticytokine trials, all which failed. cytokine response such as by cecal ligation puncture, be similar When inhibitor puncture model, they also generally lack efficacy. Compounds shown effective at reducing should re-evaluated clinically relevant

参考文章(76)
Kevin J. Tracey, Yuman Fong, David G. Hesse, Kirk R. Manogue, Annette T. Lee, George C. Kuo, Stephen F. Lowry, Anthony Cerami, Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia Nature. ,vol. 330, pp. 662- 664 ,(1987) , 10.1038/330662A0
Liza Green, Daniel G. Remick, David Newcomb, Gerald Bolgos, Antibiotic treatment influences outcome in murine sepsis: mediators of increased morbidity. Shock. ,vol. 10, pp. 110- 117 ,(1998) , 10.1097/00024382-199808000-00005
H. Lenk, St. Tanneberger, U. M�ller, J. Ebert, T. Shiga, Phase II clinical trial of high-dose recombinant human tumor necrosis factor. Cancer Chemotherapy and Pharmacology. ,vol. 24, pp. 391- 392 ,(1989) , 10.1007/BF00257449
Daniel Remick, Prerana Manohar, Gerald Bolgos, Jorge Rodriguez, Lyle Moldawer, Gordon Wollenberg, Blockade of tumor necrosis factor reduces lipopolysaccharide lethality, but not the lethality of cecal ligation and puncture Shock. ,vol. 4, pp. 89- 95 ,(1995) , 10.1097/00024382-199508000-00002
Daniel Remick, Cytokine therapeutics for the treatment of sepsis: why has nothing worked? Current Pharmaceutical Design. ,vol. 9, pp. 75- 82 ,(2003) , 10.2174/1381612033392567
Patrick Arndt, E. Abraham, Immunological therapy of sepsis: experimental therapies. Intensive Care Medicine. ,vol. 27, ,(2001) , 10.1007/S001340000574
Derek C. Angus, Walter T. Linde-Zwirble, Jeffrey Lidicker, Gilles Clermont, Joseph Carcillo, Michael R. Pinsky, Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Critical Care Medicine. ,vol. 29, pp. 1303- 1310 ,(2001) , 10.1097/00003246-200107000-00002
T. Kohno, M. T. Brewer, S. L. Baker, P. E. Schwartz, M. W. King, K. K. Hale, C. H. Squires, R. C. Thompson, J. L. Vannice, A second tumor necrosis factor receptor gene product can shed a naturally occurring tumor necrosis factor inhibitor. Proceedings of the National Academy of Sciences of the United States of America. ,vol. 87, pp. 8331- 8335 ,(1990) , 10.1073/PNAS.87.21.8331
E. A. Carswell, L. J. Old, R. L. Kassel, S. Green, N. Fiore, B. Williamson, An endotoxin-induced serum factor that causes necrosis of tumors Proceedings of the National Academy of Sciences of the United States of America. ,vol. 72, pp. 3666- 3670 ,(1975) , 10.1073/PNAS.72.9.3666